Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 1060469 Tablets in Healthy Subjects and Otherwise Healthy Patients With Asthma up to GINA Treatment Step 2 (Phase I, Randomised, Placebo-controlled, Double-blind Within Dose Groups)
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2016
Price : $35 *
At a glance
- Drugs BI 1060469 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 13 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jul 2015 Planned End Date changed from 1 Aug 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
- 30 Jul 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.